Cancer - Synthekine, Inc.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT06544330

A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A COMBINATION AUTOLOGOUS CD19 CAR T CELL THERAPY (SYNCAR-001 + STK-009) IN SUBJECTS WITH SEVERE, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS

Drug

SYNCAR-001 + STK-009

Condition

Refractory systemic lupus erythematosus